Proteome Sciences PLC Substantial Contract Win (1842L)
12 Mai 2022 - 8:01AM
UK Regulatory
TIDMPRM
RNS Number : 1842L
Proteome Sciences PLC
12 May 2022
Prior to publication, the information contained within this
announcement was deemed by the Company to constitute inside
information as stipulated under the UK Market Abuse Regulations.
With the publication of this announcement, this information is now
considered to be in the public domain.
12 May 2022
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Substantial contract win for Proteome Sciences
London, 12 May, 2022. Proteome Sciences is pleased to announce
that the Company has secured a contract from a major US academic
group to evaluate changes on the proteome and phospho-proteome of
tissue and blood samples taken from persons with and without a
neurodegenerative disease. The contract value is in excess of
GBP0.5m and we expect the study to be completed this year.
Commenting on the contract, Richard Dennis, Chief Commercial
Officer of Proteome Sciences said:
"We are pleased that the SysQuant workflows that we offer has
been selected by our client to quantitate the
proteomic/phosphoproteomic changes in these research samples. By
using the TMTpro Ô reagents we are able to analyse 17 samples and
one reference in one mass spectrometry experiment, so are able to
deliver data from this large sample set in a timely manner and
still be able to better quantitate smaller proteomic
differences."
- Ends -
For further information:
Proteome Sciences plc
Richard Dennis, Chief Commercial Tel: +44 (0)20 7043 2116
Officer
Dr Mariola Soehngen, Chief Executive
Officer
Dr Ian Pike, Chief Scientific
Officer
Allenby Capital Limited (AIM Nominated Adviser & Broker)
John Depasquale/ Jeremy Porter Tel: +44 (0)20 3328 5656
About Proteome Sciences plc. ( www.proteomics.com )
Proteome Sciences plc is a specialist provider of contract
proteomics services to enable drug discovery, development and
biomarker identification, and employs proprietary workflows for the
optimum analysis of tissues, cells and body fluids. SysQuant(R) and
TMT(R)MS2 are unbiased methods for identifying and contextualising
new targets and defining mechanisms of biological activity, while
analysis using Super-Depletion and TMTcalibrator(TM) provides
access to over 8,500 circulating plasma proteins for the discovery
of disease-related biomarkers. Targeted assay development using
mass spectrometry delivers high sensitivity, interference-free
biomarker analyses in situations where standard ELISA assays are
not available.
The Company has its headquarters in London, UK, with laboratory
facilities in Frankfurt, Germany.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTUASBRUAUVAAR
(END) Dow Jones Newswires
May 12, 2022 02:01 ET (06:01 GMT)
Proteome Sciences (AQSE:PRM.GB)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Proteome Sciences (AQSE:PRM.GB)
Historical Stock Chart
Von Dez 2023 bis Dez 2024